Nucera, Nehs, Nagarkatti et al. genic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140:209 –221. 26 Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424 – 430. 27 Salerno P, De Falco V, Tamburrino A et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carci- noma cells. J Clin Endocrinol Metab 2010;95:450 – 455. 28 Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009;94:1493–1499. 29 Tuttle RM, Leboeuf R. Investigational therapies for metastatic thyroid car- cinoma. J Natl Compr Canc Netw 2007;5:641– 646. 30 Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 2009;23:713–722. 31 Xing M. BRAF mutation in papillary thyroid cancer: Pathogenic role, mo- lecular bases, and clinical implications. Endocr Rev 2007;28:742–762. 32 Nucera C, Goldfarb M, Hodin R et al. Role of B-Raf(V600E) in differen- tiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 2009;1795:152–161. 33 Poulikakos PI, Zhang C, Bollag G et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464: 427– 430. 34 Hatzivassiliou G, Song K, Yen I et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431– 435. 309 35 Patel MK, Lymn JS, Clunn GF et al. Thrombospondin-1 is a potent mitogen and chemoattractant for human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:2107–2114. 36 Chandrasekaran S, Guo NH, Rodrigues RG et al. Pro-adhesive and chemo- tactic activities of thrombospondin-1 for breast carcinoma cells are medi- ated by 3 1 integrin and regulated by insulin-like growth factor-1 and CD98. J Biol Chem 1999;274:11408 –11416. 37 Iyer V, Pumiglia K, DiPersio CM. 3 1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: A novel mechanism of integrin-mediated MMP gene expression. J Cell Sci 2005;118:1185– 1195. 38 Majack RA, Mildbrandt J, Dixit VM. Induction of thrombospondin mes- senger RNA levels occurs as an immediate primary response to platelet- derived growth factor. J Biol Chem 1987;262:8821– 8825. 39 Kwong LN, Chin L. The brothers RAF. Cell 2010;140:180 –182. 40 Emery CM, Vijayendran KG, Zipser MC et al. MEK1 mutations confer re- sistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009; 106:20411–20416. 41 Yoshimoto K, Iwahana H, Fukuda A et al. Role of p53 mutations in endo- crine tumorigenesis: Mutation detection by polymerase chain reaction- single strand conformation polymorphism. Cancer Res 1992;52:5061– 5064. www.TheOncologist.com